Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Briacell Therapeutics Corp (BCTX)

Briacell Therapeutics Corp (BCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,014
  • Shares Outstanding, K 15,982
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,300 K
  • 60-Month Beta 1.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BCTX with:

Options Overview Details

View History
  • Implied Volatility 234.41% ( +16.79%)
  • Historical Volatility 103.45%
  • IV Percentile 87%
  • IV Rank 49.86%
  • IV High 438.74% on 04/12/24
  • IV Low 31.24% on 07/18/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 11
  • Volume Avg (30-Day) 16
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 10,952
  • Open Int (30-Day) 10,978

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/24
See More
  • Average Estimate -0.55
  • Number of Estimates 1
  • High Estimate -0.55
  • Low Estimate -0.55
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -71.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2699 +13.39%
on 05/24/24
2.4400 -40.98%
on 05/09/24
-0.7500 (-34.25%)
since 04/24/24
3-Month
1.2699 +13.39%
on 05/24/24
3.7300 -61.39%
on 02/26/24
-2.0400 (-58.62%)
since 02/23/24
52-Week
1.2699 +13.39%
on 05/24/24
7.5900 -81.03%
on 08/28/23
-4.5900 (-76.12%)
since 05/24/23

Most Recent Stories

More News
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 13, 2023 – USA News Group  –  Sufferers of many different ailments saw reason to grow their hope in 2022 when...

ONCY : 1.0900 (+2.83%)
ONC.TO : 1.53 (+2.68%)
FULC : 7.21 (-2.83%)
RNA : 27.45 (-0.07%)
BCTX : 1.4400 (+0.70%)
BCT.TO : 1.94 (-1.52%)
GILD : 65.68 (-0.74%)
Stocks in play: BriaCell Therapeutics Corp.

Announced that it has received approval from FDA on its pivotal registrational study design for Bria-IMT™ ...

BCTX : 1.4400 (+0.70%)
Five Top Companies Fighting for the Treatment of Metastatic Breast Cancer

A significant medical breakthrough is needed in the fight against metastatic breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of...

LLY : 807.43 (-0.13%)
PBYI : 4.00 (+0.25%)
GILD : 65.68 (-0.74%)
IMGN : 31.23 (unch)
BCTX : 1.4400 (+0.70%)
BCT.TO : 1.94 (-1.52%)
There are Positive Developments in the Treatment of Metastatic Breast Cancer

A significant medical breakthrough is desperately needed in the fight against metastatic breast cancer. As it stands right now, metastatic breast cancer has no cure and has proven resistant to many cancer...

LLY : 807.43 (-0.13%)
PBYI : 4.00 (+0.25%)
GILD : 65.68 (-0.74%)
IMGN : 31.23 (unch)
BCTX : 1.4400 (+0.70%)
BCT.TO : 1.94 (-1.52%)
Five Impressive Metastatic Cancer Treatment Stocks to Own Today

A significant medical breakthrough is desperately needed in the fight against breast cancer. At the moment, according to the American Cancer Society, more than 3.1 million women in the United States alone...

LLY : 807.43 (-0.13%)
PBYI : 4.00 (+0.25%)
GILD : 65.68 (-0.74%)
IMGN : 31.23 (unch)
BCTX : 1.4400 (+0.70%)
BCT.TO : 1.94 (-1.52%)
Positive Developments for Breast Cancer Care Attracting Big Investor Attention

A significant medical breakthrough is sorely needed in the fight against breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of invasive...

BCTX : 1.4400 (+0.70%)
PFE : 28.88 (+0.66%)
GILD : 65.68 (-0.74%)
PBYI : 4.00 (+0.25%)
MRK : 129.49 (-1.22%)
BCT.TO : 1.94 (-1.52%)
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – March 24, 2023 – USA News Group  –  Treatments for various forms of breast cancer continue to evolve, with several new...

BCTX : 1.4400 (+0.70%)
ONCY : 1.0900 (+2.83%)
ONC.TO : 1.53 (+2.68%)
CTMX : 1.7500 (-4.37%)
BCT.TO : 1.94 (-1.52%)
RLAY : 6.82 (-2.29%)
HOLX : 73.80 (-0.26%)
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

/PRNewswire/ -- USA News Group - Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in...

BCTXW : 0.5199 (+4.00%)
ONC.TO : 1.53 (+2.68%)
BCT.TO : 1.94 (-1.52%)
ONCY : 1.0900 (+2.83%)
CTMX : 1.7500 (-4.37%)
BCTX : 1.4400 (+0.70%)
RLAY : 6.82 (-2.29%)
HOLX : 73.80 (-0.26%)
FDA’s Wave of Fast Track Designations Pushing Momentum in Healthcare Sector in 2023

USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food and Drug Administration (FDA) granted several approvals and new Fast Track designations towards...

ONCY : 1.0900 (+2.83%)
ONC.TO : 1.53 (+2.68%)
RHHBY : 31.6000 (-0.60%)
FULC : 7.21 (-2.83%)
RNA : 27.45 (-0.07%)
BCTX : 1.4400 (+0.70%)
BCT.TO : 1.94 (-1.52%)
GILD : 65.68 (-0.74%)
Breast Cancer Treatment Options Evolved Over the Last 12 Months, Bringing More Hope for 2023

USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in nature and giving hope to families dealing with a fateful...

BCTX : 1.4400 (+0.70%)
ONCY : 1.0900 (+2.83%)
ONC.TO : 1.53 (+2.68%)
CTMX : 1.7500 (-4.37%)
BCT.TO : 1.94 (-1.52%)
RLAY : 6.82 (-2.29%)
HOLX : 73.80 (-0.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

BriaCell Therapeutics Corp. is an immuno-oncology focused biotechnology company. It developed a patented whole-cell vaccine, cancer immunotherapy technology called the `BriaVax` vaccine for cancer. The company's technology consists of Bria-IMT(TM), Bria-OTS(TM) and BriaDx(TM) which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 1.7501
2nd Resistance Point 1.6201
1st Resistance Point 1.5300
Last Price 1.4400
1st Support Level 1.3099
2nd Support Level 1.1799
3rd Support Level 1.0898

See More

52-Week High 7.5900
Fibonacci 61.8% 5.1757
Fibonacci 50% 4.4300
Fibonacci 38.2% 3.6842
Last Price 1.4400
52-Week Low 1.2699

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar